The Journal of Croatian Pharmaceutical Society

Acta Pharmaceutica

<abstract><title style='display:none'>Abstract</title> Our previous reports showed that the cyclic-AMP-response element-binding protein (CREB) served as a proto-oncogene in the process of tumorigenesis and mediated the growth and metastatic activity of renal cancer cells. Our study, therefore, explored the role of CREB in sorafenib- -inhibited cell proliferation, migration and invasion. Renal cancer cells were cultured in medium containing sorafenib for 12, 24, 48 and 72 h. The MTT assay was used to study the cytotoxic effects of sorafenib. Cell invasion and migration were assayed in wound healing and transwell experiments, respectively. Protein expression levels were evaluated by western blotting. The results show that sorafenib treatment decreased cell viability in a dose- and time-dependent manner. Sorafenib inhibited cell migration and invasion and decreased the expression of MMP-2 and MMP-9. Moreover, addition of the recombinant plasmid pCI-neo/ CREB (PN) reversed the sorafenib-induced inhibition of cell proliferation, migration and invasion. These results show that CREB is associated with the sorafenib-induced inhibition of proliferation, migration and invasion.</abstract>

Abstract

Keywords

<article-title>The Transcription Factor Creb is Involved in Sorafenib-Inhibited Renal Cancer Cell Proliferation, Migration and Invasion</article-title>

The Transcription Factor Creb is Involved in Sorafenib-Inhibited Renal Cancer Cell Proliferation, Migration and Invasion

Acta Pharmaceutica is covered by the following services: <UL> <LI>Baidu Scholar </LI> <LI>CABI (over 50 subsections) </LI> <LI>Case </LI> <LI>Chemical Abstracts Service (CAS) - CAplus </LI> <LI>Chemical Abstracts Service (CAS) - SciFinder </LI> <LI>CNKI Scholar (China National Knowledge Infrastructure) </LI> <LI>CNPIEC - cnpLINKer </LI> <LI>Derwent Drug File </LI> <LI>Dimensions </LI> <LI>DOAJ (Directory of Open Access Journals) </LI> <LI>EBSCO </LI> <LI>Embase </LI> <LI>ExLibris </LI> <LI>Google Scholar </LI> <LI>Japan Science and Technology Agency (JST) </LI> <LI>J-Gate </LI> <LI>Journal Citation Reports/Science Edition </LI> <LI>JournalGuide </LI> <LI>JournalTOCs </LI> <LI>KESLI-NDSL (Korean National Discovery for Science Leaders) </LI> <LI>Medline </LI> <LI>MyScienceWork </LI> <LI>Naver Academic </LI> <LI>Naviga (Softweco) </LI> <LI>ProQuest </LI> <LI>PubMed </LI> <LI>PubsHub </LI> <LI>QOAM (Quality Open Access Market) </LI> <LI>ReadCube </LI> <LI>Reaxys </LI> <LI>Referativnyi Zhurnal (VINITI) </LI> <LI>SCILIT </LI> <LI>SCImago (SJR) </LI> <LI>SCOPUS </LI> <LI>Semantic Scholar </LI> <LI>Sherpa/RoMEO </LI> <LI>TDNet </LI> <LI>Ulrich's Periodicals Directory/ulrichsweb </LI> <LI>WanFang Data </LI> <LI>Web of Science - Biological Abstracts </LI> <LI>Web of Science - BIOSIS Previews </LI> <LI>Web of Science - Essential Science Indicators </LI> <LI>Web of Science - Science Citation Index Expanded </LI> <LI>WorldCat (OCLC) </LI> <LI>X-MOL </LI></UL>

Acta Pharmaceutica ist in den folgenden Services indiziert: <UL> <LI>Baidu Scholar </LI> <LI>CABI (over 50 subsections) </LI> <LI>Case </LI> <LI>Chemical Abstracts Service (CAS) - CAplus </LI> <LI>Chemical Abstracts Service (CAS) - SciFinder </LI> <LI>CNKI Scholar (China National Knowledge Infrastructure) </LI> <LI>CNPIEC - cnpLINKer </LI> <LI>Derwent Drug File </LI> <LI>Dimensions </LI> <LI>DOAJ (Directory of Open Access Journals) </LI> <LI>EBSCO </LI> <LI>Embase </LI> <LI>ExLibris </LI> <LI>Google Scholar </LI> <LI>Japan Science and Technology Agency (JST) </LI> <LI>J-Gate </LI> <LI>Journal Citation Reports/Science Edition </LI> <LI>JournalGuide </LI> <LI>JournalTOCs </LI> <LI>KESLI-NDSL (Korean National Discovery for Science Leaders) </LI> <LI>Medline </LI> <LI>MyScienceWork </LI> <LI>Naver Academic </LI> <LI>Naviga (Softweco) </LI> <LI>ProQuest </LI> <LI>PubMed </LI> <LI>PubsHub </LI> <LI>QOAM (Quality Open Access Market) </LI> <LI>ReadCube </LI> <LI>Reaxys </LI> <LI>Referativnyi Zhurnal (VINITI) </LI> <LI>SCILIT </LI> <LI>SCImago (SJR) </LI> <LI>SCOPUS </LI> <LI>Semantic Scholar </LI> <LI>Sherpa/RoMEO </LI> <LI>TDNet </LI> <LI>Ulrich's Periodicals Directory/ulrichsweb </LI> <LI>WanFang Data </LI> <LI>Web of Science - Biological Abstracts </LI> <LI>Web of Science - BIOSIS Previews </LI> <LI>Web of Science - Essential Science Indicators </LI> <LI>Web of Science - Science Citation Index Expanded </LI> <LI>WorldCat (OCLC) </LI> <LI>X-MOL </LI></UL>

Editor-in-Chief Svjetlana Luterotti, Zagreb, Croatia Managing Editor Maja Jakševac Mikša, Zagreb, Croatia Editorial Board Karmela Barišić (Zagreb), Jelena Filipović-Grčić (Zagreb), Mojca Kerec Kos (Ljubljana), Jasmina Lovrić (Zagreb), Svjetlana Luterotti (Zagreb), Željan Maleš (Zagreb), Izidor Sosič (Ljubljana), Željka Vanić (Zagreb), Donatella Verbanac (Zagreb), Branka Zorc (Zagreb), Alenka Zvonar Pobirk (Ljubljana) International Advisory Board Rudolf Bauer (Graz), Cristian-Catalin Gavat (Iasi), Atillâ Hincal (Ankara), Ivan Jalšenjak (Zagreb), Hans E. Junginger (Marburg), M. Zahirul I. Khan (Melbourne), Péter Mátyus (Budapest), Beatrice Perissutti (Trieste), Stane Srčič (Ljubljana) Technical Editor Branka Zorc, Zagreb, Croatia Contacts Professor Svjetlana Luterotti, PhD Editor-in-Chief Croatian Pharmaceutical Society, Masarykova 2, HR-10000 Zagreb, Croatia e-mail: <A href="mailto:svjetlana.luterotti@pharma.hr">svjetlana.luterotti@pharma.hr</A>; <A href="mailto:svjetlana.luterotti@gmail.com">svjetlana.luterotti@gmail.com</A> Professor Branka Zorc, PhD Technical Editor Faculty of Pharmacy and Biochemistry University of Zagreb, HR-10000 Zagreb, Ante Kovačića 1 e-mail: <A href="mailto:bzorc.AP@farmaceut.org">bzorc.AP@farmaceut.org</A> Maja Jakševac-Mikša, PhD Managing Editor Croatian Pharmaceutical Society, HR-10000 Zagreb, Masarykova 2 phone: +385 1 48 72 849; fax: +385 1 48 72 853 e-mail: <A href="mailto:maja.jaksevac-miksa@zg.t-com.hr">maja.jaksevac-miksa@zg.t-com.hr</A>; <A href="mailto:hfd-fg-ap@zg.t-com.hr">hfd-fg-ap@zg.t-com.hr</A>; <A href="mailto:info@farmaceut.org">info@farmaceut.org</A> Section Editors Karmela Barišić Mojca Kerec Kos Željka Vanić Donatella Verbanac Publisher De Gruyter Poland Bogumiła Zuga 32A Str. 01-811 Warsaw, Poland phone: +48 22 701 50 15

Please submit your manuscripts to Acta Pharmaceutica via email to: <A href="mailto:svjetlana.luterotti@gmail.com">svjetlana.luterotti@gmail.com</A> or <A href="mailto:svjetlana.luterotti@pharma.hr">svjetlana.luterotti@pharma.hr</A> PUBLICATION CHARGES Because of the high cost of preparing and publishing articles in Acta Pharmaceutica payment of publication fee is mandatory for all articles accepted for publication. Current charge is 900 € per manuscript (excl. VAT). For more information please visit <A href="https://sciendo-parsed-data-feed.s3.eu-central-1.amazonaws.com/ACPH/Instrucions_for_Authors.pdf">Instructions for Authors</A>. Open Access Statement The journal is an Open Access journal that allows a free unlimited access to all its contents without any restrictions upon publication to all users. <A href="https://sciendo-parsed-data-feed.s3.eu-central-1.amazonaws.com/ACPH/Open_Access_License.doc">Open Access License</A>

Acta Pharmaceutica (AP) is an international, scientific, multidisciplinary journal, devoted to the pharmaceutical and allied sciences, which contains articles predominantly on core biomedical and health subjects. The aim of AP is to increase the impact of pharmaceutical research in academia, industry and laboratories. With a strong emphasis on quality and originality, AP publishes reports from the discovery of a drug up to clinical practice, in the form of preliminary and short communications, original research papers and reviews. Book reviews are published also. AP is a quarterly, single-blind peer-reviewed journal in biomedicine with fully open access and “early bird” platform. All articles are submitted to scrutinized evaluation and fair judgement. AP above all puts scientific honesty and integrity. To reach the highest standards in publication ethics all the parties (authors, editors, reviewers) are required to behave responsibly and ethically. This implies submittance by authors on an exclusive basis, of only their own and new data; novelty and originality are prioritized. Also, secure handling of confidential data by reviewers and editors is a must. AP is indexed in numerous world top international bibliographic bases, like Clarivate Analytics´s Web of Science® Core Collection (SCI-Expanded, JCR/Science Edition, etc.), EMBASE/Excerpta Medica, MEDLINE/PubMed, Scopus/SCImago, and others. According to SCImago JR it is a Q2 journal (pharmaceutical sciences) with a steadily increasing Clarivate JIF value reaching 2.230 in 2020 Topics covered are: <UL> <LI>drug design </LI> <LI>molecular modelling/docking studies </LI> <LI>pharmaceutical chemistry/medicinal chemistry </LI> <LI>drug metabolism </LI> <LI>analytics of drugs </LI> <LI>pharmaceutical technology/formulation studies/nanosystems/cosmetology </LI> <LI>pharmaceutical biotechnology </LI> <LI>pharmaceutics/biopharmacy (including pharmacokinetics) and pharmacodynamics </LI> <LI>drug delivery/disposition and stability </LI> <LI>pharmacognosy and　phytopharmacy </LI> <LI>pharmacology (clinical and animal) </LI> <LI>toxicology </LI> <LI>clinical pharmacy </LI> <LI>pharmacovigilance </LI> <LI>pharmaceutical and clinical biochemistry </LI> <LI>pharmaceutical biology with genetics/pharmacogenomics/cell biology </LI> <LI>pharmacoepidemiology/pharmacoeconomics/social pharmacy </LI> <LI>physical pharmacy </LI> <LI>radiopharmaceuticals </LI> <LI>medicine (including diagnostics and therapy) </LI> <LI>peptide and protein chemistry/protein design </LI></UL> Why subscribe and read <UL> <LI>To get informed on the latest research in pharmaceutical and related sciences. </LI></UL> Why submit <UL> <LI>fair and constructive peer review by the experts in the field, </LI> <LI>editorial help and language revision services, </LI> <LI>articles abstracted by online indexing services, </LI> <LI>listed in WoS MJL by Clarivate. </LI></UL> Archiving Sciendo archives the contents of this journal in <A href="https://www.portico.org/">Portico</A> - digital long-term preservation service of scholarly books, journals and collections. Plagiarism Policy The editorial board is participating in a growing community of <A href="https://www.crossref.org/services/similarity-check/">Similarity Check System's</A> users in order to ensure that the content published is original and trustworthy. Similarity Check is a medium that allows for comprehensive manuscripts screening, aimed to eliminate plagiarism and provide a high standard and quality peer-review process.

Acta Pharmaceutica

The Transcription Factor Creb is Involved in Sorafenib-Inhibited Renal Cancer Cell Proliferation, Migration and Invasion

Shuaishuai Huang,
Shuaishuai Huang,
Pinger Cui,
Pinger Cui,
Shuangxia Lin,
Shuangxia Lin,
Xuping Yao,
Xuping Yao,
Xue Wang,
Xue Wang,
Yu Ren oraz
Yu Ren oraz
Guobin Weng
Guobin Weng

Data publikacji: 03 Oct 2018

Tom & Zeszyt: Tom 68 (2018) - Zeszyt 4 (December 2018)

Zakres stron: 497 - 506

Otrzymano: 13 Jun 2018

Przyjęty: 16 Jul 2018

Dziennik i szczegóły wydania

Acta Pharmaceutica

Podgląd PDF

Najnowsze artykuły

Acta Pharmaceutica

The Transcription Factor Creb is Involved in Sorafenib-Inhibited Renal Cancer Cell Proliferation, Migration and Invasion

Shuaishuai Huang,Shuaishuai Huang,Pinger Cui,Pinger Cui,Shuangxia Lin,Shuangxia Lin,Xuping Yao,Xuping Yao,Xue Wang,Xue Wang,Yu Ren orazYu Ren orazGuobin WengGuobin Weng

Data publikacji: 03 Oct 2018

Tom & Zeszyt: Tom 68 (2018) - Zeszyt 4 (December 2018)

Zakres stron: 497 - 506

Otrzymano: 13 Jun 2018

Przyjęty: 16 Jul 2018

Dziennik i szczegóły wydania

Acta Pharmaceutica

Podgląd PDF

Najnowsze artykuły

Shuaishuai Huang,
Shuaishuai Huang,
Pinger Cui,
Pinger Cui,
Shuangxia Lin,
Shuangxia Lin,
Xuping Yao,
Xuping Yao,
Xue Wang,
Xue Wang,
Yu Ren oraz
Yu Ren oraz
Guobin Weng
Guobin Weng